Back to Treatments

Treatment

Intravenous Immunoglobulin (IVIG)

3
Conditions
22
Trials
3,550
Participants
60%
Average Safety

Condition Evidence

Acute hepatitis E

8 trials · 50 participants

45% effectiveness · 65% safety

Encephalitis

12 trials · 2,500 participants

80% effectiveness · 55% safety

Myocarditis

2 trials · 1,000 participants

60% effectiveness · 60% safety
Intravenous Immunoglobulin (IVIG) | DFDA